Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 28

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 28
---
 we will receive approval for our products in the United States or
in other countries or, if approved, that we or a partner will achieve a significant level of sales, or that we develop any products.
If we fail to partner, develop or commercialize our products, we may be forced to curtail or cease operations.

We are also in the pre-clinical stages of research
and development with the vaccine and ARB new product candidates using nanoparticles-based technologies. These new indications and product
candidates will require significant costs to advance through the development stages. Even if such product candidates are advanced through
clinical trials, the results of such trials may not gain FDA approval. Even if approved, our products may not be commercially successful.

<div align='center'>13</div>

If We Cannot Successfully Develop our Products and Technology, Our Business Model Would Need to be Changed or We Would Be Required to Change Our Priorities and Opportunities.

There are many products and programs that seem
promising to us which we could pursue. However, with limited resources, we may decide to change priorities and shift programs

The choices we make will be dependent upon numerous
contemporaneous factors, some of which we cannot predict. We cannot be sure that our business model, as it currently exists or as it
may evolve, will enable us to become profitable or to sustain operations. We have not demonstrated our ability to successfully complete
large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party
to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization or manage an operational
public company. Because of our limited operating history outside of being a research company, we have limited insight into trends that
may emerge and affect our business, and errors may be made in developing an approach to address those trends and the other challenges
faced by per-clinical biopharmaceutical companies such as our Company. Failure to adequately respond to such trends and challenges could
cause our business, results of operations and financial condition to suffer or fail. Further, our limited operating history may make
it difficult for our stockholders to make any predictions about our likelihood of future success or viability. Even if we were to achieve
successful clinical results in our programs, successful approval, marketing, and sales of our novel therapeutics are also critical to
the financial future of our company. Our human-use products are not yet approved for sale in the United States and other jurisdictions,
and we may never obtain